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INTRODUCTION
Vogt-Koyanagi-Harada (VKH) syndrome or uveoen-
cephalitis is a rare systemic disease of melanocyte-
containing organs.1 In the eye, VKH presents as
granulomatous panuveitis with exudative retinal
detachment. It is also often associated with skin,
auditory and neurologic manifestations. It is found in
Asian, Middle Eastern, Hispanic, and Native American
populations and is more common in females.2 The
diagnosis of VKH syndrome is based on the revised
criterion set by an International Committee on
Nomenclature which has defined 3 categories of
disease: complete, incomplete and probable VKH.3
Treatment involves topical and systemic steroids and
immuno-suppressants.
We report a case of VKH syndrome with a brief literature
review.
CASE REPORT
A 26-year-old male, diagnosed with VKH in an eye clinic
in Sydney, Australia, came to our clinic for follow-up. He
presented there with bilateral red eye and decreased
vision–right more than the left. There was no history of
any neurological complaints. On examination, he was
found to have bilateral anterior uveitis with exudative
retinal detachment in the right eye. There were no
auditory, neurological or dermatological symptoms or
signs present at the time of initial presentation. Figure 1
shows the optical coherence tomography (OCT) report
of his right eye at presentation. Fluorescein fundal
angiography (FFA) was done as well at that time but the
report is not available. A series of blood tests (e.g.
complete blood count, angiotensin converting enzyme,
antinuclear antibody, enzyme-linked immunosorbent
assay) were done to rule out other causes of uveitis. He
was put on oral (120 mg/day) and topical steroids.
Three months after, he was diagnosed with VKH, he
came to our clinic while still on a tapering dose of steroid
(prednisolone) - 15 mg/day. While his vision had
improved on medication, he still had complaints of
decreased vision, metamorphasia and glare during night
driving, and had recently developed decreased hearing
in both ears.
On examination, the best-corrected visual acuity in his
right eye was 20/40. The left eye had a 20/20 vision. He
had an intraocular pressure of 10 mmHg in both eyes.
Anterior segment of both eyes was normal. Examination
of the posterior segment showed a dull macular reflex in
the right eye with no retinal detachment. The left eye
was normal. OCT and FFA three months after the
initiation of treatment (Figure 1 b and c) showed
resolution of exudative retinal detachment. Amsler Grid
showed wavy lines. He was referred to a skin specialist
but had no skin signs. His audiogram showed
sensorineural hearing loss in the high frequency range in
both ears. According to the criterion set by the
International Committee on Nomenclature,4 the case
met the first four criteria and was diagnosed as
incomplete VKH (Table I). The dose of steroid
(prednisolone) was increased to 60 mg/day and tapered
over the next 3 months. His best corrected vision in the
right improved to 20/20 from 20/40. His near vision is
N/6 in both the eyes. Hearing improved and
metamorphasia also decreased slightly. The only
remaining complaint has been the glare during night
driving 6-month post-treatment while on maintenance
dose of steroids 5 mg/day. A year later, glare also
resolved. Only slight metamorphasia is present but does
not interfere with his daily life. He is not taking any
medicine for the last four months.
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ABSTRACT
Vogt-Koyanagi-Harada (VKH) syndrome is a rare multisystem disease of melanocyte containing organs. It is characterized
by diffuse granulomatous inflammation involving various organs including eye. VKH syndrome is usually sporadic, but
some familial cases have also been reported indicating a hereditary basis. VKH is not associated with mortality but it may
result in long-term complications such as decreased vision associated with cataract, glaucoma and choroidal
neovascularization. For successful outcomes, early aggressive treatment using systemic steroids with gradual tapering is
essential. This report describes a case of VKH syndrome in a 26-year-old male of Pakistan origin who was successfully
treated with systemic steroids. The case is briefly contextualised within wider literature.
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DISCUSSION
VKH has been reported in diverse populations (e.g.
Asian, Arab, Hispanic, and Native American) with female
preponderance. In this case, the patient, though
diagnosed in Australia, was an Asian of Pakistani origin,
the typical age range for this syndrome is 20 - 50 years.
However, rarely the disease may present in children as
well. VKH is more common among females, with a
female to male ratio of 2:1.2
The disease involves various melanocyte containing
organs including the eyes, ears and central nervous
systems. Though the exact etiology of the disease is
unknown, as was in this case, an autoimmune cause
has been reported in literature. There is mainly a T-cell
mediated immune response against the autoantigens
such as uveal autoantigen, TRP1, TRP2, MART 1,
PMel-17/gp100, KU-MEL-1, PAX3 on melanocytes. The
changes noticed in the immune system of VKH patient
include reduction in the number and activity of regulatory
T-cells and decreased apoptosis of lymphocytes.5
There is an increased expression of major histo-
compatibility complex type II (MHC II). This autoimmune
pathogenesis is supported by the fact that VKH is
associated with HLA-DR4 and HLA-Dw53, of the allele
subtypes, the most important are HLA-DRB1*0410 and
HLA-DRB1*0405.6 In this case, the association for HLA
was not worked up. Other possible etiologies identified
as triggering factors include viral infection, trauma,
tumors and certain medications. No such correlation
was identified in this case.
As shown in Table I, the diagnosis of this condition is
based on the revised criterion set by an International
Committee on Nomenclature which has defined 3
categories of disease: complete VKH (all 5 criteria),
incomplete VKH (criteria 1,2,3, 4 or 5), and probable
VKH (criteria 1,2,3).4 The clinical course of VKH is
divided into four clinical phases, prodromal phase
present with headache, mild fever, photophobia, and
symptoms and signs of meningoencephalitis. Lumbar
puncture at this stage may show lymphocytic
pleocytosis, proteins and increased cerebrospinal
pressure. This phase lasts for a few days to weeks with
variable severity and is noticed in only 50% of the
patients. This patient did not give the history of this
phase or did not notice this phase.
This is usually followed by the uveitic phase which lasts
a number of weeks. It is this phase in which most
patients come for medical consultation.2 This patient
also presented to the clinic in the uveitic phase, with
bilateral red eye and decreased vision-right more than
the left. Bilateral blurred vision is the most common
presenting complaint (in 70% of cases) in this phase.2
Ocular signs during this phase have been described as
bilateral posterior uveitis with retinal edema, papillitis,
serous retinal detachments, iridocyclitis, mutton-fat
keratic precipitate and iris nodules and raised IOP. This
case presented with bilateral posterior uveitis with
serous retinal detachment in the right eye. Otolaryngeal
symptoms also usually present in this stage. This patient
noticed decreased hearing and on testing was found to
have neurosensory hearing loss, which responded to
the treatment. Literature describes immunomediated
sensorineural hearing loss which is bilateral, though may
be asymmetrical and is reversible with treatment.7 Other
otolaryngeal symptoms such as tinnitus, dizziness and
vertigo were not reported by this patient. The
convalescent phase reported in 80% of patients is
associated with tissue depigmentation such as vitiligo
and poliosis, this follows the uveitic phase. Then comes
the recurrent phase which shows signs of recurrent
uveitis and ocular complications such as cataract,
glaucoma, retinal detachment, subretinal membranes
and fibrosis.8 This patient did not have a recurrence till
the last follow-up.
The diagnosis of this condition is mainly clinical and
though no specific lab tests are present, tests done in
routine for uveitis are ordered to help in differential
diagnosis which includes conditions like sympathetic
ophthalmia, sarcoidosis, primary intraocular B-cell
lymphoma, posterior scleritis, and uveal effusion
syndrome. OCT findings pre-treatment and 3 months
after treatment and FFA findings 3 months after
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Table I: VKH syndrome: diagnostic criteria and treatment.
A. Diagnostic criteria 
1. Absence of history of penetrating ocular trauma or surgery preceding 
the initial onset of uveitis.
2. Absence of clinical or laboratory history of other type of ocular disease
3. Bilateral ocular involvement.
4. Presence of neurological/auditory findings.
5. Presence of cutaneous findings not preceding onset of ocular disease 
or neurological manifestations.
Presence of criteria 1-5 (Complete VKH), Presence of criteria 1-3 plus 4 or 5
(Incomplete VKH), Presence of criteria 1-3 (Probable VKH).
B. Prognostic factors
Age, timing of intervention, vision within 1 month of treatment.
C. Treatment options
Steroids, immunosuppressant, immunoglobulins.
Figure 1 (a,b,c): (a) OCT right eye pre-treatment, (b) OCT right eye 3 months
after the initiation of treatment, (c) FFA right eye 3 months after the initiation
of treatment.
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treatment are shown in this case report. Indocyanine
green angiography (ICGA) has been shown to be the
most useful imaging modality to monitor response to the
treatment but it is currently not available in our setting.
Treatment should be early and aggressive with high-
dose oral corticosteroids; there is no advantage of
intravenous therapy over oral one.9 Early aggressive
treatment, young age, and good vision within one month
of treatment are associated with a better visual
prognosis (Table I). Treatment is associated with
complete reversal of auditory symptoms which was also
the case in this patient. It is suggested to continue the
treatment for 3 months with tapering over 6 months to a
year for good visual prognosis and to prevent
recurrences. This patient was started on high dose
steroids and then gradually the dose tapered. Patients
not responding to steroids or not tolerating its side-
effects can be treated with immunomodulatory agents,10
such as cyclosporine, tacrolimus, azathioprine, myco-
phenolate mofetil, cyclophosphamide, or chlorambucil.
Recent evidence indicates that virtually all the patients
with VKH can be successfully treated with immuno-
modulatory agent and now there is a trend to early
immunosuppressive therapy in VKH.
A limitation of this case report is that we could not get the
complete information regarding initial assessment such
as FFA at the time of presentation, dose and frequency
of topical steroids prescribed and vision within one
month of treatment (a prognostic factor) as the patient
was diagnosed in another country.
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